Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.
Also called NCT01516151
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 289 participants
- Sponsor
- Registry
-
NCT01516151
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT01516151. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Intervention (Dietary supplement)
- CaPre™
- Intervention (Dietary supplement)
- CaPre™
- Intervention (Dietary supplement)
- CaPre™
- Intervention (Drug)
- Lipid Lowering Medication
- Intervention (Dietary supplement)
- CaPre™
- Lead sponsor
- Grace Therapeutics Inc.
- Collaborator
- JSS Medical Research Inc.
Record details
- Record id
cardio:ct-nct01516151- Content hash
ddc91c3a00048d23a413e26e54d7c6b453f7401bbd6127710dbc1d832c15d32a